UY32593A - "compuestos sustituidos de 3-azetidin de 3-azetidin-1-il)(5-fenil-1,3,4-oxadiazol-2-il) metanona - Google Patents

"compuestos sustituidos de 3-azetidin de 3-azetidin-1-il)(5-fenil-1,3,4-oxadiazol-2-il) metanona

Info

Publication number
UY32593A
UY32593A UY0001032593A UY32593A UY32593A UY 32593 A UY32593 A UY 32593A UY 0001032593 A UY0001032593 A UY 0001032593A UY 32593 A UY32593 A UY 32593A UY 32593 A UY32593 A UY 32593A
Authority
UY
Uruguay
Prior art keywords
azetidin
metanone
oxadiazol
phenyl
compounds
Prior art date
Application number
UY0001032593A
Other languages
English (en)
Inventor
Lars Anders Mikael Johansson
Robert Andrew Judkins
Li Lanna
Bjoern Christian Ingvar Loefberg
Persson Joachim
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY32593A publication Critical patent/UY32593A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

En la presente se describen compuestos de fórmula I donde R1, R2, R3, R4, R5, A, X, Y son tal como se definen en la memoria, su uso en composiciones farmacéuticas y en métodos de tratamiento o profilaxis de una enfermedad o afección relacionada con la hormona de concentración de malanina
UY0001032593A 2009-05-01 2010-04-30 "compuestos sustituidos de 3-azetidin de 3-azetidin-1-il)(5-fenil-1,3,4-oxadiazol-2-il) metanona UY32593A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17463009P 2009-05-01 2009-05-01

Publications (1)

Publication Number Publication Date
UY32593A true UY32593A (es) 2010-11-30

Family

ID=42290768

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032593A UY32593A (es) 2009-05-01 2010-04-30 "compuestos sustituidos de 3-azetidin de 3-azetidin-1-il)(5-fenil-1,3,4-oxadiazol-2-il) metanona

Country Status (23)

Country Link
US (1) US8110566B2 (es)
EP (1) EP2424870B1 (es)
JP (1) JP5763052B2 (es)
KR (1) KR20120023044A (es)
CN (2) CN103936751A (es)
AR (1) AR076516A1 (es)
AU (1) AU2010243341B2 (es)
BR (1) BRPI1014387A2 (es)
CA (1) CA2759230A1 (es)
DK (1) DK2424870T3 (es)
ES (1) ES2562831T3 (es)
HR (1) HRP20160128T1 (es)
HU (1) HUE026856T2 (es)
MX (1) MX2011011618A (es)
PL (1) PL2424870T3 (es)
PT (1) PT2424870E (es)
RU (1) RU2526055C2 (es)
SA (1) SA110310332B1 (es)
SI (1) SI2424870T1 (es)
SM (1) SMT201600041B (es)
TW (1) TW201100433A (es)
UY (1) UY32593A (es)
WO (1) WO2010125390A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010507619A (ja) * 2006-10-25 2010-03-11 ノイロサーチ アクティーゼルスカブ オキサジアゾール及びチアジアゾール化合物並びにニコチン性アセチルコリン受容体調節物質としてのその使用
EA201291384A1 (ru) * 2010-07-06 2013-07-30 Астразенека Аб Терапевтические агенты 976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
HU230880B1 (hu) 2015-04-15 2018-11-29 Richter Gedeon Nyrt Indol származékok
JP2023509800A (ja) * 2020-01-10 2023-03-09 コンシナンス セラピューティクス， インコーポレイテッド 薬物の治療的組み合わせ及びそれらの使用方法
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2292931T3 (es) * 2002-02-01 2008-03-16 Novo Nordisk A/S Amidas de azetidinas, pirrolidinas, piperidinas y azepanos aminoalquilo sustituidos.
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
EP1553089B1 (en) 2002-07-30 2009-09-30 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
WO2004072018A1 (ja) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited アミン誘導体
US20060293298A1 (en) * 2003-04-10 2006-12-28 Bamford Mark J Compounds
GB0400193D0 (en) 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
JP2007517868A (ja) 2004-01-07 2007-07-05 アストラゼネカ アクチボラグ 治療薬ｉ
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
TW200538098A (en) 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
ATE432926T1 (de) * 2004-07-26 2009-06-15 Lilly Co Eli Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung
SI1805169T1 (sl) 2004-10-18 2009-06-30 Lilly Co Eli Inhibitorji histamin h3 receptorja, njihova priprava in terapevtske uporabe
MX2007007226A (es) 2004-12-17 2007-08-21 Lilly Co Eli Antagonistas receptores novedosos de hormona concentradora de melanina (mch).
EP1831194A4 (en) 2004-12-21 2009-12-02 Astrazeneca Ab HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
WO2006130075A1 (en) 2005-05-31 2006-12-07 Astrazeneca Ab Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
WO2007011284A1 (en) 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
JP2009522354A (ja) 2006-01-06 2009-06-11 アストラゼネカ・アクチエボラーグ 化合物
CA2659155A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1
WO2008020799A1 (en) 2006-08-18 2008-02-21 Astrazeneca Ab Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists
WO2008068265A1 (en) 2006-12-05 2008-06-12 Janssen Pharmaceutica N.V. Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
EP2089397B1 (en) 2006-12-14 2012-08-29 Eli Lilly & Company 5- [4- (azetidin-3-yl0xy) -phenyl]-2-phenyl-5h-thiaz0l0 [5,4-c]pyridin-4-0ne derivatives and their use as mch receptor antagonists
JP2010524962A (ja) 2007-04-17 2010-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド オーロラキナーゼ阻害剤のための創薬法
ES2369955T3 (es) 2007-08-22 2011-12-09 F. Hoffmann-La Roche Ag Pirrolidina-aril-éteres como antagonistas de receptores de nk3.
PL2212283T3 (pl) * 2007-10-17 2012-01-31 Sanofi Sa Podstawione karboksyamidy N-fenylobipirolidyny i ich zastosowanie terapeutyczne
WO2009154132A1 (ja) * 2008-06-19 2009-12-23 萬有製薬株式会社 スピロジアミン-ジアリールケトオキシム誘導体

Also Published As

Publication number Publication date
PT2424870E (pt) 2016-03-17
AU2010243341A1 (en) 2011-11-03
KR20120023044A (ko) 2012-03-12
SI2424870T1 (sl) 2016-03-31
WO2010125390A1 (en) 2010-11-04
CN102459279A (zh) 2012-05-16
BRPI1014387A2 (pt) 2017-06-06
AU2010243341B2 (en) 2014-02-13
SA110310332B1 (ar) 2013-12-10
CA2759230A1 (en) 2010-11-04
TW201100433A (en) 2011-01-01
MX2011011618A (es) 2011-11-18
CN102459279B (zh) 2014-06-25
US20100280000A1 (en) 2010-11-04
PL2424870T3 (pl) 2016-05-31
ES2562831T3 (es) 2016-03-08
EP2424870B1 (en) 2015-12-16
RU2526055C2 (ru) 2014-08-20
HRP20160128T1 (hr) 2016-02-26
AR076516A1 (es) 2011-06-15
SMT201600041B (it) 2016-02-25
US8110566B2 (en) 2012-02-07
DK2424870T3 (en) 2016-02-15
EP2424870A1 (en) 2012-03-07
JP2012525365A (ja) 2012-10-22
JP5763052B2 (ja) 2015-08-12
CN103936751A (zh) 2014-07-23
HUE026856T2 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
ECSP12011935A (es) Triazolopiridinas
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
CR20140113A (es) Imidazopiridazinas sustituidas con amino
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
ECSP088184A (es) Derivados de benzoquinazolina y su uso en el tratamiento de enfermedades óseas
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
BR112012015967A2 (pt) uso de compostos de fórmula geral (i) e composição farmacêutica
UY32593A (es) "compuestos sustituidos de 3-azetidin de 3-azetidin-1-il)(5-fenil-1,3,4-oxadiazol-2-il) metanona
CR10192A (es) Compuestos de amido y su uso como productos farmaceuticos
CU20110119A7 (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematológicas
ECSP066375A (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ECSP12012338A (es) Triazolopiridinas sustituidas
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
UY31780A (es) Fenoxibenzamidas sustituidas
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
EA200602049A1 (ru) Пролекарства стероидов с андрогенным действием
BR112012013199A8 (pt) Composto, composição farmacêutica, e , uso de um composto
IN2011KN05169A (es)

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127